Cambrian explosion of ADCs at AACR24

The rapid evolution of ADC formats currently under way — sometimes referred to as the modality’s Cambrian explosion — continued full tilt at this year’s AACR meeting. Presentations showcased at least six emerging payloads, and over a dozen companies presented bispecific versions of the modality, proposing 20 different target pairs.

Success breeds success, and antibody-drug conjugates (ADCs) dominated the presentations at the 2024 American Association for Cancer Research (AACR) meeting, as companies look to expand the modality into new commercial opportunities...